Scancell is developing a broad portfolio of products for the treatment of cancer. The first clinical stage products are based on the Company’s two complementary vaccine technologies, ImmunoBody® and Moditope® which are designed to induce potent CD8 and CD4 cytotoxic T cell responses, respectively. Whereas other cancer vaccines stimulate low frequency, low avidity T cell responses that fail to control tumour growth, Scancell’s novel therapies stimulate high avidity responses that efficiently destroy tumours.

In addition, Scancell has acquired a third proprietary technology, AvidMab™, that confers potent direct tumour cell killing properties to humanised monoclonal antibodies (mAbs). Scancell has used this technology to produce a number of cytotoxic mAbs that recognise glycan-containing glycoproteins and glycolipids on the cell surface of cancer cells.

Due to the immediacy of the COVID-19 pandemic, Scancell has recently initiated its COVIDITY programme to develop a COVID-19 vaccine in collaboration with scientists at the University of Nottingham and Nottingham Trent University.